2 active not recruiting, 2 completed, 1 terminated, 1 withdrawn. 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Ovarian Endometrioid Tumor: new trials by email Literature Review of Ovarian Endometrioid Tumor trials Research Report on Ovarian Endometrioid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer NXP800 - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvectis Pharma, Inc. | 45 | 2021-12-31 | 2026-08-06 |
| Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer Atezolizumab, Bevacizumab - Ovarian Endometrioid Tumor, Fallopian Tube Cancer | Phase 2 | Withdrawn | University Health Network, Toronto | 2021-07-16 | 2023-06-06 | |
| Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Laboratory Biomarker Analysis, Monitoring Device, Physical Activity - Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm | Phase 2 | Completed | Roswell Park Cancer Institute | 9 | 2017-06-27 | 2021-09-02 |
| Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Berzosertib, Carboplatin, Gemcitabine Hydrochloride - Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2017-05-16 | 2026-07-31 |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Biospecimen Collection, Carboplatin, Cediranib Maleate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 579 | 2016-03-28 | 2026-10-01 |
| Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer Dexamethasone, Laboratory Biomarker Analysis, Valproic Acid - Adnexal Mass, Borderline Ovarian Epithelial Tumor | Phase 1 | Completed | Barbara Ann Karmanos Cancer Institute | 50 | 2015-08-01 | 2019-08-14 |
Ovarian Neoplasms (5) · Fallopian Tube Neoplasms (4) · Adenocarcinoma (1) · Carcinoma (1) · Neoplasms (1)
Adnexal Diseases (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Neoplasms by Site (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Gonadal Disorders (5) · Neoplasms (5) · Ovarian Diseases (5) · Fallopian Tube Diseases (4)
Carboplatin (2) · Gemcitabine (2) · Bevacizumab (1) · Calcium Dobesilate (1) · Dexamethasone (1) · Doxorubicin (1) · Exercise (1) · Magnetic Resonance Spectroscopy (1) · Monitoring, Physiologic (1) · Paclitaxel (1) · Specimen Handling (1) · Taxes (1) · Valproic Acid (1) · atezolizumab (1) · auricularum (1)
National Cancer Institute (NCI) (2) · Barbara Ann Karmanos Cancer Institute (1) · Nuvectis Pharma, Inc. (1) · Roswell Park Cancer Institute (1) · University Health Network, Toronto (1)
United States (5) · Canada (2) · Japan (1) · South Korea (1) · United Kingdom (1)
Andrea E Wahner Hendrickson (1) · Emese Zsiros (1) · Ira Winer (1) · Joyce F Liu (1) · Stephanie Lheureux, M.D. (1) · Susana Banerjee, Dr (1) · Udai Banerji, Prof (1)
PMID 35170751, PMID 35290101, PMID 37185961
N01CM00099 (1), P30CA015083 (1), P30CA022453 (1), U10CA180868 (1), UM1CA186686 (1), UM1CA186709 (1)